



(formerly WellFirst Health)

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

Commercial (Small & Large Group) ASO Exchange/ACA
 Medicare Advantage (MAPD)

Intravenous, Intramuscular, and Subcutaneous Ketamine for Chronic Pain, Mental Health and Substance Use Disorders MB2300

Covered Service: NO

Prior Authorization

Required: NO

Additional Information: Prescribed by (or in consultation with) pain specialists with prior authorization through The Plan Pharmacy Services.

Medicare Policy: Prior authorization is not required for Medicare Cost products (Dean Care Gold) and Medicare Supplement (Select) when this drug is provided by participating providers. Prior authorization is required if a member has Medicare primary and the plan secondary coverage. This policy is not applicable to our Medicare Replacement products.

Wisconsin Medicaid Policy

Coverage of prescription drug benefits is administered by the Wisconsin Medicaid program. Coverage of medical drug benefits is administered by the Wisconsin Medicaid fee-for-service program. Medical drugs not paid on a fee-for-service basis by the Wisconsin Medicaid program are covered by the plan with no PA required.

1.0 FDA Indication

1.1 Ketamine

1.1.1 Ketamine hydrochloride injection is FDA-approved for the induction of anesthesia prior to the administration of other general anesthetic agents, and to supplement low-potency agents for procedural sedation. IV ketamine for the treatment of chronic pain or symptoms of all mental health (including major depressive disorder, obsessive compulsive disorder, suicidal cognition, and post-traumatic stress syndrome) and substance-related disorders is an off-label use. KETARx was FDA approved in August 2025, but is not available yet in the U.S.

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

1.2 Treatment Guidelines/Consensus statements:

- 1.2.1 American Society of Regional Anesthesia and Pain Medicine – Joint Consensus Guideline (2018) – IV Ketamine for Chronic Pain
 - 1.2.1.1 Weak evidence supporting use of IV ketamine for short-term improvement in patients with spinal cord injury pain
 - 1.2.1.2 Moderate evidence supporting use of IV ketamine for improvement in patients with complex regional pain syndrome (CRPS) up to 12 weeks
 - 1.2.1.3 Weak or no evidence for immediate improvement for other pain conditions, including mixed neuropathic pain, fibromyalgia, cancer pain, ischemic pain, headache, and spinal pain
- 1.2.2 American Psychiatric Association (APA) – Consensus Guideline (2017) – IV Ketamine for mood disorders
 - 1.2.2.1 Available studies had relatively small sample sizes, did not evaluate the longer-term efficacy of ketamine, and provided limited data on safety.
 - 1.2.2.2 Clinicians must consider the limitations of available data and potential risks associated with ketamine treatment, including suicidal ideation and potential for substance abuse.

2.0 Policy / Criteria:

- 2.1 IV Ketamine is considered not covered due to insufficient evidence to demonstrate long-term clinical efficacy and safety for treatment of chronic pain
 - 2.1.1 Two trials with a total of 100 patients provide limited evidence that courses of IV ketamine may provide temporary relief (2 to 4 weeks) to some chronic pain patients in some settings. Neither of the RCTs used an active control, raising concerns about placebo effects.
 - 2.1.2 A phase 2 study investigated use of anesthetic dosing of ketamine in 20 patients with refractory CRPS. Symptoms were either long standing(range, 6-68 months), spreading, or rapidly progressive, and refractory to conventional nonmedical (physical therapy, psychological approaches), or pharmacologic (mono- or combined therapy) and interventional treatments (at least 3) including selective nerve blocks, epidural analgesia, brachial plexus blocks, sympathetic ganglion blocks, intravenous regional sympathetic blocks, spinal cord stimulation, surgical sympathectomy, or intrathecal drug delivery systems. Patients were intubated and mechanically ventilated (except for the first 3 patients). Ketamine infusion was titrated up to a dose of 7 mg/kg/h with infusion over 5 days, and then tapered downward until consciousness was attained. Midazolam was co-administered to a level of deep sedation to attenuate agitation and other AEs. Outcomes were assessed at 1 week and

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

1, 3, and 6 months after treatment. Pain intensity decreased from a numeric rating scale of 9 at baseline to 0.5 at 1 week and remained low (2.0) at 6 months. Three patients relapsed but with lower pain (3.8) than at baseline. Pain relief was 94%, 89%, and 79% at 1, 3, and 6 months, respectively. Upper- and lower-extremity movement improved from 3.2 at baseline to 0.4 at 6 months for arm movement and from 2.3 at baseline to 0.6 at 6 months for walking. At 6 months, there was a significant difference in the ability to perform activities of daily living; 1 patient rated total impairment; 3, severe impairment; 6, moderate impairment; and 10 patients, no impairment. Impairment in the ability to work was rated at baseline as complete by 11, severe by 5, and moderate by 4 patients. At 6 months, 2 patients remained unable to work, 4 had moderate impairment, and 14 patients reported no impairment. Psychotropic AEs resolved in the first week in most patients, although 5 patients reported difficulties with sleeping and recurring nightmares for 1 month following treatment. Muscle weakness was reported in all patients for up to 4 to 6 weeks' post treatment. As indicated by the authors, a strong placebo response to this intensive intervention was expected, and a large, multicenter RCT would be needed to definitively establish efficacy and safety. At this time, the beneficial effect of IV administration of ketamine is considered suggestive but not proven; additional trials are needed.

2.2 IV Ketamine is considered not covered due to insufficient evidence to demonstrate long-term clinical efficacy and safety for treatment of symptoms of all mental health (including major depressive disorder, obsessive compulsive disorder, suicidal cognition, and post-traumatic stress syndrome) and substance-related disorders.

2.2.1 Small randomized, controlled trials have demonstrated efficacy of ketamine in producing significant improvement in depressive symptoms in the short-term with effects generally lasting days or weeks. However, the long-term safety and efficacy with prolonged use of this medication, and the effects of repeated treatments have not been clinically evaluated.

2.2.2 Acute benefit of ketamine is only short lived and can produce psychotomimetic effects. Because of this, the APA recommends not to use ketamine/esketamine in patients with previous psychotic symptoms.

2.2.3 Ketamine is also potentially neurotoxic, particularly with longer-term administration.

2.2.4 Following a successful course of treatment with ketamine or electroconvulsive therapy, relapse is nearly two times greater with ketamine.

3.0 Policy Rationale



(formerly WellFirst Health)

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

- 3.1 The intense treatment protocols, the severity of adverse events, and the limited treatment durability raise questions about the net health benefit of IV ketamine for chronic pain or mental health and substance-related disorders.
- 3.2 Additional clinical trials are needed to evaluate the long-term efficacy and safety of repeat courses of IV ketamine for chronic pain or mental health and substance-related disorders.
- 3.3 The evidence is insufficient to determine that IV ketamine results in an improvement in the net health outcome.

Comment(s):

1.0 *Codes and descriptors listed in this document are provided for informational purposes only and may not be all inclusive or current. Listing of a code in this drug policy does not imply that the service described by the code is a covered or non-covered service. Benefit coverage for any service is determined by the member's policy of health coverage with the plan. Inclusion of a code in the table does not imply any right to reimbursement or guarantee claim payment. Other drug or medical policies may also apply.

1.1 NDC and HCPCS codes

Medication Name		How Supplied	National Drug Code (NDC)	HCPCS code
Brand	Generic			
Ketamine	Ketamine	Various	Numerous	J3490

	Committee/Source	Date(s)
Document	Medical Policy Committee/Health Services	
Created:	Division/Pharmacy Services	February 15, 2023
Revised:	Medical Policy Committee/Health Services Division/Pharmacy Services	August 21, 2025
Reviewed:	Medical Policy Committee/Health Services Division/Pharmacy Services	February 15, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services	August 21, 2024
	Medical Policy Committee/Health Services Division/Pharmacy Services	August 21, 2025

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

Effective: 08/21/2025

Published: 09/01/2025

References:

1. Attal N, Gaude V, Brasseur L, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. *Neurology*. Feb 82000; 54(3):564-574. PMID 10680784.
2. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. *J Pain Symptom Manage*. Jun 1999; 17(6):429-433. PMID 10388248.
3. Kvarnstrom A, Karlsten R, Quiding H, et al. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. *Acta Anaesthesiol Scand*. Aug 2003; 47(7):868-877. PMID 12859309.
4. Medrik-Goldberg T, Lifschitz D, Pud D, et al. Intravenous lidocaine, amantadine, and placebo in the treatment of sciatica: a double-blind, randomized, controlled study. *Reg Anesth Pain Med*. Nov-Dec 1999;24(6):534-540. PMID 10588558.
5. Sorensen J, Bengtsson A, Ahlner J, et al. Fibromyalgia--are there different mechanisms in the processing of pain? A double-blind crossover comparison of analgesic drugs. *J Rheumatol*. Aug 1997; 24(8):1615-1621. PMID 9263160.
6. Wallace MS, Ridgeway BM, Leung AY, et al. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. *Anesthesiology*. Jan 2000; 92(1):75-83. PMID 10638902.
7. Wu CL, Tella P, Staats PS, et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double-blind, active placebo-controlled, crossover trial. *Anesthesiology*. Apr 2002; 96(4):841-848. PMID 11964590.
8. Vlainich R, Issy AM, Sakata RK. Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. *Clin J Pain*. May 2011; 27(4):285-288. PMID 21178598.
9. Reutens DC, Fatovich DM, Stewart-Wynne EG, et al. Is intravenous lidocaine clinically effective in acute migraine? *Cephalalgia*. Dec 1991;11(6):245-247. PMID 1790567.
10. Hand PJ, Stark RJ. Intravenous lignocaine infusions for severe chronic daily headache. *Med J Aust*. Feb 21 2000; 172(4):157-159. PMID 10772585.
11. Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. *Cephalalgia*. Dec 2003; 23(10):963-971. PMID 14984229.
12. Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. *Clin J Pain*. Mar-Apr 2006; 22(3):266-271. PMID 16514327.
13. Carroll I, Gaeta R, Mackey S. Multivariate analysis of chronic pain patients undergoing lidocaine infusions: increasing pain severity and advancing age predict likelihood of clinically meaningful analgesia. *Clin J Pain*. Oct 2007; 23(8):702-706. PMID 17885349.

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

14. Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. *Cochrane Database Syst Rev*. 2005(4):CD003345. PMID 16235318. *Vyondys 53 Prescribing Information*. Cambridge, MA: Sarepta Therapeutics, Inc.; December 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf. Accessed January 2, 2020.
15. Tremont-Lukats IW, Challapalli V, McNicol ED, et al. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. *Anesth Analg*. Dec 2005; 101(6):1738-1749. PMID 16301253.
16. Rathmell JP, Ballantyne JC. Local anesthetics for the treatment of neuropathic pain: on the limits of metaanalysis. *Anesth Analg*. Dec 2005; 101(6):1736-1737. PMID 16301252.
17. Przeklaska-Muszynska A, Kocot-Kepska M, Dobrogowski J, et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. *Pharmacol Rep*. Oct 2016; 68(5):1069-1075. PMID 27552062
18. Finnerup NB, Biering-Sorensen F, Johannesen IL, et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. *Anesthesiology*. May 2005; 102(5):1023-1030. PMID 15851891
19. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. *Anesth Analg*. Dec 2003; 97(6):1730-1739. PMID 14633551.
20. Motov S, Mai M, Pushkar I, et al. A prospective randomized, double-dummy trial comparing IV push low dose ketamine to short infusion of lowdose ketamine for treatment of pain in the ED. *Am J Emerg Med*. Aug 2017; 35(8):1095-1100. PMID 28283340
21. Wertli MM, Kessels AG, Perez RS, et al. Rational pain management in complex regional pain syndrome 1 (CRPS 1)--a network meta-analysis. *PainMed*. Sep 2014; 15(9):1575-1589. PMID 25234478.
22. Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. *Pain*. Dec 15 2009; 147(1-3):107-115. PMID 19783371.
23. Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. *Pain*. Oct 2009; 145(3):304-311. PMID 19604642.
24. O'Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. *Cochrane Database Syst Rev*. 2013; 4:CD009416. PMID 23633371.
25. Correll GE, Maleki J, Gracely EJ, et al. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. *Pain Med*. Sep 2004; 5(3):263-275. PMID 15367304.
26. Kiefer RT, Rohr P, Ploppa A, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. *Pain Med*. Nov 2008; 9(8):1173-1201. PMID 18266808.

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

27. Noppers IM, Niesters M, Aarts LP, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. *Pain*. Sep 2011;152(9):2173-2178. PMID 21546160.
28. Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. *Eur J Pain*. Oct 2011; 15(9):942-949. PMID 21482474.
29. Eichenberger U, Neff F, Sveticic G, et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. *Anesth Analg*. Apr 2008; 106(4):1265-1273, table of contents. PMID 18349204.
30. Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. *Pain Med*. Feb 2012; 13(2):263-269. PMID 21939497.
31. Webster LR, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. *Am J Ther*. Jul-Aug 2006; 13(4):300-305. PMID 16858163.
32. Kvarnstrom A, Karlsten R, Quiding H, et al. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. *Acta Anaesthesiol Scand*. Apr 2004; 48(4):498-506. PMID 15025615.
33. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. *Pain Physician*. May-Jun 2010; 13(3):245-249. PMID 20495588.
34. American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. *Anesthesiology*. Apr 2010; 112(4):810-833.
35. Intravenous Anesthetics for the Treatment of Chronic Pain. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (2017 November) 5.01.16.
36. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. *JAMA Psychiatry*. 2017; 74(4):399.
37. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, APA Council of Research Task Force on Novel Biomarkers and Treatments. *Am J Psychiatry*. 2015 Oct; 172(10):950-66.
38. Domany Y, Bleich-Cohen M, Tarrasch R, Meidan R, Litvak-Lazar O, Stoppleman N, Schreiber S, Bloch M, Hendl T, Sharon H. *Br J Psychiatry*. 2019; 214(1):20. Epub 2018 Sep 24.